◎Coherus BioSciencesが5500万ドルのシリーズC資金調達完了

Coherus BioSciences, Inc.

2014/5/20 10:07

◎Coherus BioSciencesが5500万ドルのシリーズC資金調達完了

AsiaNet 56780

共同JBN 0538 (2014.5.20)

【レッドウッドシティー(米カリフォルニア州)2014年5月19日PRN=共同JBN】バイオシミラー生物製剤に注力する有力な生物製剤プラットフォーム企業であるCoherus BioSciences, Inc.(以下Coherus)は19日、シリーズC優先投資ラウンドで5500万ドルの調達を完了したと発表した。この取引には既存の投資家であるSofinnova Ventures、Lilly Ventures、Vivo Capitalに加えて、新たにKKR & Co. L.P. (KKP)、Venrock、 RA Capital Management、Rock Springs Capital、Fidelity Biosciences の各社が加わった。




▽Coherus Biosciencesについて

Coherus Biosciencesは、人生を変えるような医薬品に対する患者のアクセスを世界的に広げる高品質バイオシミラー治療薬に注力する、有力な生物製剤プラットフォーム企業である。Coherusはサンフランシスコ・ベイエリアに本社を構え、米国の第1世代生物療法産業の構築を支援したバイオテク先駆者グループによって創設され、所有権とインセンティブ共有を通じてまとまったサービスプロバイダーの戦略的コンソーシアムを活用する、独自かつ協業的ビジネスモデルを開発した。Coherusの世界的な商業化のための提携関係は、欧州、アジア、中南米トップのバイオ製薬企業が含まれる。



Beth Jimison



Logo - http://photos.prnewswire.com/prnh/20120507/SF01448LOGO

ソース:Coherus BioSciences, Inc.

Coherus BioSciences Secures $55 Million Series C Financing


REDWOOD CITY, Calif., May 19, 2014 /PRN=KYODO JBN / --

   Coherus BioSciences, Inc. ("Coherus"), a leading biologics platform company

focused on biosimilars, announced today the closing of a Series C Preferred

investment round raising $55 million. New investors KKR & Co. L.P. ("KKR"),

Venrock, RA Capital Management, Rock Springs Capital and Fidelity Biosciences

joined existing investors Sofinnova Ventures, Lilly Ventures and Vivo Capital

in the transaction.

   "We are very pleased to have the confidence and financial support of such an

extraordinary group of health care investors," said Denny Lanfear, President

and CEO of Coherus. "Since its founding four years ago, Coherus has made

excellent progress on its goals of moving biosimilar biologics into Phase 3

trials and onto the market. The capital resources provided by our investors

will allow us to prosecute our development plans, optimize our partnering

strategies and deliver essential therapeutics to patients faster."

   As part of the transaction, Ali Satvat, Director on KKR's health care

investing team, will join the Board of Directors of Coherus. "We are excited to

support Denny and his experienced team on their growth initiatives to transform

the biologics market," said Mr. Satvat. "We believe that the Coherus platform

is well-positioned to succeed given its product pipeline and strong scientific

and technical capabilities."

   Since its inception, Coherus has raised over $220 million from equity and

non-dilutive licensing fees and milestones.

   About Coherus BioSciences, Inc.

   Coherus is a leading biologics platform company focused on delivering

high-quality biosimilar therapeutics that will expand patient access to

life-changing medications worldwide. Headquartered in the San Francisco Bay

Area and founded by a group of biotech pioneers who helped build America's

first generation biotherapeutics industry, Coherus has developed a

collaborative business model that leverages a strategic consortium of service

providers aligned through ownership and shared incentives. Coherus' global

commercialization partnerships include top-tier biopharma companies in Europe,

Asia, and Latin America.

   Biosimilars are intended for use in place of existing, branded biologics to

treat a range of chronic and often life-threatening diseases, with the

potential to reduce costs and expand patient access. For additional

information, please visit: www.coherus.com.

   CONTACT: Beth Jimison



     Logo - http://photos.prnewswire.com/prnh/20120507/SF01448LOGO

   SOURCE: Coherus BioSciences, Inc.